Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
$102.71
$0.52(1.17%)
At close: 4:00 PM EST
$102.71
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$29.17 - $112.43
Previous CloseN/A
Volume180.68K
Average Volume (3M)2.00M
Market Cap
$19.86B
Enterprise Value$8.78B
Total Cash (Recent Filing)$1.93B
Total Debt (Recent Filing)$158.46M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 02, 2026EPS Estimate
-1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding193,319,810
10 Day Avg. Volume1,354,732
30 Day Avg. Volume2,004,772
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-12.92
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.31K
Enterprise Value/Ebitda-8.78
Forecast
1Y Price Target
$81.88Price Target Upside-20.28% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyHigh response and disease control rates reported with daraxonrasib, including notable responses in combination settings, indicate a potential efficacy advantage versus existing chemotherapy options in pancreatic cancer.
Clinical Trial TimelinesFaster-than-expected enrollment in the Phase 3 RASolute 302 trial could bring forward interim and final survival analyses, delivering key binary readouts that materially de-risk the program.
Pipeline Expansion And Strategic OptionalityBroad registrational development across multiple cancer types and optional combination strategies, such as pairing with intensive chemotherapy, expand commercial pathways and reduce reliance on a single trial outcome.
Bears Say
Competitive Landscape And Clinical VisibilityNew rival Phase 3 programs targeting the same KRAS G12D population, combined with limited recent updates on zoldonrasib, may intensify enrollment competition and weaken perceived differentiation in the clinic.
Financial Performance And LiquiditySignificant annualized cash burn raises the prospect of future financing needs, which could dilute shareholders or pressure the stock if capital markets access becomes constrained.
Market Sentiment And PositioningElevated short interest as a portion of the float signals investor skepticism that could amplify downside moves during execution setbacks or disappointing updates.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $112.43 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $19.86B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Mar 02, 2026 which is in 52 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Aug 10, 2020. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Overvalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.57.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 193,319,810 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.438%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.88 (-20.28% Downside)
$81.88 (-20.28% Downside)
Blogger Sentiment
Neutral
RVMD Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 684.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $450.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.69%
12-Months-Change
Fundamentals
Return on Equity
-60.76%
Trailing 12-Months
Asset Growth
27.73%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD Company Deck
RVMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong progress in clinical programs and regulatory achievements for daraxonrasib, as well as a solid financial position supported by strategic partnerships. However, these positive developments were somewhat offset by increased operating expenses and significant net losses.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$81.88
▼(-20.28% Downside)
Technical Analysis
Ownership Overview
2.22% Insiders
24.08% Mutual Funds
51.15% Other Institutional Investors
10.40% Public Companies and Individual Investors